Making confident clinical development decisions at ASCPT

Microtracers can be used to increase the information density in your early clinical trials. The information on metabolites in First-In-Man studies will de-risk the clinical development trajectory because of the 100% certainty of not finding any human unique metabolites at a later stage. TNO is the only organization in Europe with a biomedical Accelerator Mass Spectrometer (AMS) that enables this research.

The focus and experience of TNO in the field of microtracer research extends to:
- Metabolite profiling and identification in First-In-Man studies
- Absolute bioavailability in early clinical development
- Early PK of biologicals (peptides, proteins, ADCs etc) and small molecules using microdosing
- Pediatric PK studies to optimize dosing strategies and increase recruitment rates dramatically

At the ASCPT, TNO will present its capabilities in the field of microtracer AMS studies showing that these studies will accelerate drug development. Advantages of our auto-combustion based AMS in comparison to the conventional graphitization based AMS will be demonstrated. In addition, we will show the strengths of using our simultaneous data acquisition using high resolution MS (for metabolite identification) and AMS (for metabolite quantification) approach.

We look forward to meeting you at our booth, number 40.